Boston Scientific to Collaborate with Affinergy on Novel Cardiovascular Stent Coatings.RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. -- Affinergy, Inc., a Duke University spinout spin·out n. An instance of spinning out: a motorist who was injured in a spinout. with a proprietary site-specific biological delivery system, recently signed a collaboration agreement with Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, (NYSE NYSE See: New York Stock Exchange : BSX BSX Bermuda Stock Exchange BSX Bandai Satellaview-X BSX Bicycle Super-X (Cross) ) to investigate new coatings for cardiovascular stents. Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. "Boston Scientific has a long history as the innovation and marketshare leader in cardiovascular markets," said Peyton Anderson, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Affinergy. "Affinergy is very proud to work with Boston Scientific exclusively in the field of cardiovascular stents during this collaboration. Our team is excited to work in a large medical device field where improving clinical outcomes can positively affect patients' lives. Affinergy looks forward to building this relationship and moving our coatings into development as rapidly as possible." "Affinergy is excited about the agreement with Boston Scientific," said Daniel Kenan, MD, Ph.D., Affinergy's scientific co-founder from Duke University. "We expect Affinergy's peptide linker systems can make a critical difference and look forward to accelerating these programs." About Affinergy, Inc. Affinergy develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer. surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused on developing coatings and medical devices for the orthopedic and cardiovascular markets. Affinergy's technology was patented at Duke University and the company has been incubated at Becton Dickinson's research center in Research Triangle Park. Affinergy was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. For more information, visit www.affinergy.com or contact Peyton Anderson at (919) 345-4732. About Boston Scientific Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit www.bostonscientific.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion